INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM

Core Points - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Actinium securities during the Class Period have until May 26, 2025, to apply as Lead Plaintiff [2] - Actinium's stock price experienced a significant decline of nearly 60% following a regulatory update regarding its Biologics License Application for Iomab-B [4] Company Overview - Actinium Pharmaceuticals, Inc. is involved in the development of therapies for patients with cancer, specifically focusing on acute myeloid leukemia [4] - The company faced a setback when the FDA deemed the Phase 3 SIERRA trial inadequate for supporting a BLA filing for Iomab-B [4] Legal Context - Pomerantz LLP, a law firm specializing in corporate and securities class litigation, is leading the class action against Actinium [5] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]